XML 48 R33.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Loss before income tax - Additional Information (Details) € in Millions | 1 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | ---
Jun. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2021 EUR (€) | Feb. 29, 2020 USD ($) | Dec. 31, 2019 USD ($) | Oct. 31, 2019 USD ($) | Oct. 31, 2018 USD ($) milestone | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Jun. 30, 2023 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2017 EUR (€)
Disclosure Of Loss Before Income Tax [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized from up-front payment as deferred consideration |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |
Receipt on non refundable up-front payment upon reaching product regulatory milestone |  |  |  |  |  |  | $ 25,000,000 |  |  |  |  |
Escalating milestone payments | milestone |  |  |  |  |  |  | 6 |  |  |  |  |
Pre-launch inventory recognized |  |  |  |  |  |  |  | $ 21,600,000 |  | $ 22,400,000 |  |
Manufacturing Commercialization Expenses |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Pre-launch inventory recognized |  |  |  |  |  |  |  | (800,000) | $ 1,600,000 |  |  |
Grunenthal |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payment received |  |  |  |  |  | $ 15,000,000 |  |  |  |  |  |
Milestone payment received |  |  |  |  | $ 2,500,000 |  |  |  |  |  |  |
Percentage of patients to provide regulatory harmonization, cost efficiencies and streamlined timelines | 20.00% |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payments receivable | $ 17,500,000 |  |  |  |  |  |  |  |  |  |  |
Cumulative milestone payments reachable amount | 1,000,000,000 |  |  |  |  |  |  |  |  |  |  |
Revenue recognized for right of use license of IP |  |  |  |  |  |  |  | 0 | 0 |  |  |
Grunenthal | Top of Range | Clinical, Manufacturing, Regulatory and Reimbursement Approval |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Amount entitled to be received upon reaching product clinical and regulatory milestones and reimbursement targets are achieved | $ 112,500,000 |  |  |  |  |  |  |  |  |  |  |
Tasly |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Deferred consideration milestone consideration recognized |  |  |  |  |  |  | $ 20,000,000 |  |  |  |  |
Revenue recognized from up-front payment as deferred consideration |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |
Tasly | License |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized from up-front payment as deferred consideration |  |  |  |  |  |  |  | 0 | 0 |  |  |
TiGenix NV |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Royalty income |  |  |  |  |  |  |  | 200,000 | 200,000 |  |  |
TiGenix NV | License |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Current contract liabilities |  |  |  |  |  |  |  |  |  |  | $ 5,900,000 | € 5.0
Non-current contract liabilities |  |  |  |  |  |  |  |  |  |  | $ 5,900,000 | € 5.0
Revenue from contracts with customers |  | $ 1,200,000 | € 1.0 |  |  |  |  |  |  |  |  |
TiGenix NV | Top of Range | License |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue, remaining performance obligation, variable consideration amount | € |  |  | € 9.0 |  |  |  |  |  |  |  |  |
JCR Pharmaceuticals Co. Ltd |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Royalties receivable under sales-based milestones |  |  |  |  |  |  |  | $ 3,200,000 | $ 3,200,000 |  |  |

X
- Definition The amount of current contract liabilities. [Refer: Contract liabilities] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2023-01-01 -Paragraph 105 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_CurrentContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of non-current contract liabilities. [Refer: Contract liabilities] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2023-01-01 -Paragraph 105 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_NoncurrentContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2023-01-01 -Paragraph 114 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2023-01-01 -Paragraph 113 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of income arising from royalties. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_RevenueFromRoyalties
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount Entitled to be received on non refundable up-front payment upon reaching product regulatory milestone. + References No definition available. + Details
Name: | meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount Entitled To Be Received Upon Reaching Product Clinical And Regulatory Milestones And Reimbursement Targets Are Achieved + References No definition available. + Details
Name: | meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cumulative milestone payments reachable amount. + References No definition available. + Details
Name: | meso_CumulativeMilestonePaymentsReachableAmount
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Deferred consideration milestone consideration recognized. + References No definition available. + Details
Name: | meso_DeferredConsiderationMilestoneConsiderationRecognized
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Disclosure Of Loss Before Income Tax [Line Items] + References No definition available. + Details
Name: | meso_DisclosureOfLossBeforeIncomeTaxLineItems
Namespace Prefix: | meso_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payment received. + References No definition available. + Details
Name: | meso_MilestonePaymentReceived
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non refundable up front payment received. + References No definition available. + Details
Name: | meso_NonRefundableUpFrontPaymentReceived
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non-refundable upfront payments receivable. + References No definition available. + Details
Name: | meso_NonRefundableUpfrontPaymentsReceivable
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number Of Escalating Milestone Payments + References No definition available. + Details
Name: | meso_NumberOfEscalatingMilestonePayments
Namespace Prefix: | meso_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of patients to provide regulatory harmonization, cost efficiencies and streamlined timelines. + References No definition available. + Details
Name: | meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines
Namespace Prefix: | meso_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pre launch inventory recognized. + References No definition available. + Details
Name: | meso_PreLaunchInventoryRecognized
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Revenue recognized for right of use license of IP. + References No definition available. + Details
Name: | meso_RevenueRecognizedForRightOfUseLicenseOfIP
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue recognized from up-front payment as deferred consideration. + References No definition available. + Details
Name: | meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue, remaining performance obligation, variable consideration amount + References No definition available. + Details
Name: | meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Royalties receivable under salesbased milestones. + References No definition available. + Details
Name: | meso_RoyaltiesReceivableUnderSalesBasedMilestones
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=meso_ManufacturingCommercializationExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=meso_GrunenthalGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RegulatoryEnvironmentsAxis=meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=meso_TaslyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=meso_License1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=meso_TiGenixNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=meso_JCRPharmaceuticalsCoLTDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |